Pharmafile Logo

Uniphar and ImmunityBio Partner to Support International Operational Launch and Distribution of ANKTIVA® Across Europe, the UK and MENA

- PMLiVE

Uniphar and ImmunityBio Partner to Support International Operational Launch and Distribution of ANKTIVA® Across Europe, the UK and MENA

 

[Dublin, 18th November 2026] Uniphar has today announced a strategic partnership with ImmunityBio to support the full European order-to-cash and 3PL services for ANKTIVA® (nogapendekin alfa inbakicept), an innovative immunotherapy indicated for patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ, with or without papillary tumours.

Under the partnership, Uniphar has been selected to design, implement and operate a comprehensive order-to-cash, supply chain, storage, distribution, importation and commercial support platform to support the availability and compliant supply of ANKTIVA across Europe.

Through this collaboration, Uniphar will act as an integrated operational partner, providing scalable and compliant infrastructure to support launch readiness and ongoing commercial supply across multiple international markets. The partnership brings together Uniphar’s expertise in complex pharmaceutical distribution, importation, quality oversight, financial services and operational support with ImmunityBio’s innovation in specialist oncology.

ANKTIVA is authorised in combination with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive NMIBC carcinoma in situ, with or without papillary tumours, and has received regulatory authorisations across the United States, United Kingdom, Kingdom of Saudi Arabia and European Union, according to ImmunityBio’s public communications. ImmunityBio has stated that the European Commission granted conditional marketing authorisation for ANKTIVA in combination with BCG in February 2026, covering the 27 EU member states plus Iceland, Liechtenstein and Norway.

For patients with BCG-unresponsive NMIBC, timely access to innovative treatment options remains a significant priority. This partnership establishes a robust operational model designed to support the availability of ANKTIVA across multiple markets, helping healthcare systems and clinicians access a specialist oncology therapy through a compliant and scalable supply platform.

The collaboration also reflects the growing importance of specialist commercialisation and distribution models for high-value, complex therapies. Uniphar’s established international infrastructure across Europe, MENA and other global markets positions the company to support emerging and specialty biopharmaceutical partners seeking to expand access without building extensive in-country operational infrastructure.

“This partnership reinforces Uniphar’s role as a trusted international partner for biotechnology companies bringing highly specialised therapies to patients across complex markets,” said Brian O’Shaughnessy, Chief Commercial Officer at Uniphar. “By combining our regulatory, quality, supply chain, distribution, order-to-cash capabilities, we can support ImmunityBio with a scalable platform that enables launch readiness and ongoing commercial supply for ANKTIVA.”

“Expanding access to ANKTIVA across Europe and the UK is an important step in our mission to bring this innovative immunotherapy to more patients living with BCG-unresponsive non-muscle-invasive bladder cancer,” explained Richard Adcock, President and CEO of ImmunityBio. “Uniphar’s international expertise in pharmaceutical distribution, supply chain management and commercial logistics will help support the compliant, reliable and timely delivery of ANKTIVA across these complex markets. We look forward to working together to advance the availability of ANKTIVA for patients and the healthcare professionals who care for them.”

 ENDS

This content was provided by Uniphar

Company Details

 Latest Content from  Uniphar 

Uniphar and ImmunityBio Partner to Support International Operational Launch and Distribution of ANKTIVA® Across Europe, the UK and MENA

Uniphar and ImmunityBio Partner to Support International Operational Launch and Distribution of ANKTIVA® Across Europe, the UK and MENA   [Dublin, 18th November 2026] Uniphar has today announced a strategic…

INmune Bio establishes global commercialization framework for Ebstrocel™ through strategic agreement with Uniphar

Initial focus on named-patient access in selected European and MENA markets, providing a capital-efficient foundation for broader commercialization

Governor Josh Stein marks strengthening North Carolina-Ireland trade relationship at Uniphar facility visit

The event speaker panel, from left to right: Brian Kiefel, Ireland Site Leader & CTO, Honeywell; Christopher Chung, Chief Executive Officer, EDPNC; Tom Scrivener, Group COO, Bank of America; Ambassador…

J‑Pharma Co., Ltd. and Uniphar Announce Advancement of Nanvuranlat into Phase 3 Clinical Development Following FDA Alignment and Initial Patient Enrollment

Strategic partnership enables direct progression to Phase 3, bypassing additional Phase 2 study, as first patients are randomized in global trial  TOKYO, Japan and DUBLIN, Ireland — [June 16, 2026] J‑Pharma Co., Ltd., a clinical-stage biotechnology…

Durbin PLC becomes Uniphar, bolstering medicine access amidst growing healthcare demands

Against the backdrop of widespread medicine shortages, Durbin PLC’s rebrand to Uniphar and integration into Uniphar | Global Sourcing represents a strategic move to address industry-wide challenges, expanding its sourcing…

Strategies to enhance the provider and patient EAP experience

Expanded access programs (EAPs) play a multifaceted role in the drug development life cycle, serving as a critical bridge between clinical trials and commercial availability.

Uniphar | Clinical merges with BMclinical to strengthen global clinical trial services

Leading global healthcare services provider Uniphar announces a strategic merger between Uniphar | Clinical and BMclinical, reinforcing Uniphar | Clinical’s integrated clinical supply offering and solidifying its position as a trusted partner to pharmaceutical and biotech companies worldwide.   As part of Uniphar’s global platform supporting…

Uniphar announces U.S. expansion, integrating leading companies and appointing new senior leadership

– New integration aligns U.S. operations, unifying RRD BioPharma Development, Uniphar Clinical, Diligent Health Solutions and BESTMSLs under the Uniphar brand. – Mike Ebhardt is appointed President of Uniphar Pharma…

Uniphar On Track to Achieve SBTi Target of Halving Scope 1 and 2 Emissions by 2030

[Dublin, 9th October 2025] Uniphar, a global leader in pharmaceutical and medtech solutions, is making progress towards its near-term Science Based Targets initiative (SBTi) goal of halving Scope 1 and…

Streamlining European expansion for cell and gene therapies

Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs). Europe…